Search

Your search keyword '"Srinivasan, Anandagopal"' showing total 8 results
Start Over Author "Srinivasan, Anandagopal"
8 results on '"Srinivasan, Anandagopal"'

2. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Author

Colomba, Emeline, Le Teuff, Gwénaël, Eisen, Tim, Stewart, Grant D., Fife, Kate, Larkin, James, Biondo, Andrea, Pickering, Lisa, Srinivasan, Anandagopal, Boyle, Helen, Derosa, Lisa, Sternberg, Cora N., Recine, Federica, Ralph, Christy, Saldana, Carolina, Barthélémy, Philippe, Bernhard, Jean Christophe, Gurney, Howard, Verhoest, Gregory, Vauleon, Elodie, Bigot, Pierre, Berger, Julien, Pfister, Christian, Gravis, Gwenaelle, Rodier, Jean-Michel, Culine, Stéphane, Caty, Armelle, Rolland, Frederic, Priou, Franck, Escudier, Bernard, and Albiges, Laurence

Published
2017
Full Text
View/download PDF

3. Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort.

Author

Maouche, Nadjoua, Srinivasan, Anandagopal, Leary, Heather, Collings, Freya, Tseu, Bing, Vallance, Grant D, Ramasamy, Karthik, and Kothari, Jaimal

Subjects
*THERAPEUTIC use of monoclonal antibodies, *THERAPEUTIC use of antineoplastic agents, *DRUG efficacy, *CANCER relapse, *IMMUNOMODULATORS, *CANCER patients, *DESCRIPTIVE statistics, *SURVIVAL analysis (Biometry), *MULTIPLE myeloma, *PROGRESSION-free survival, *OVERALL survival, *EVALUATION
Abstract

Daratumumab is the first anti-CD38 targeting monoclonal antibody approved as monotherapy in multiply relapsed myeloma patients who progressed following prior treatment with proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). We present real world data on the efficacy of single agent daratumumab in a cohort of 55 multiply relapsed patients treated in the UK. The median age was 72 years, the majority (96%) received ≥ 3 previous lines of treatment; 54.5% were PI-refractory, 76.4% were IMiD-refractory and 47.2% were double refractory; 20% of patients had high-risk (HR) disease. The overall response rate was 49%. After a median follow up of 9.2 months, the median progression-free survival (PFS) for the total cohort was 5.1 months. Patients who achieved a partial response or better (≥PR) demonstrated a significantly longer PFS compared to those with

Published
2023
Full Text
View/download PDF

6. sj-docx-1-opp-10.1177_10781552211067780 - Supplemental material for Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort

Author

Maouche, Nadjoua, Srinivasan, Anandagopal, Leary, Heather, Collings, Freya, Tseu, Bing, Vallance, Grant D, Ramasamy, Karthik, and Kothari, Jaimal

Subjects
FOS: Clinical medicine, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-opp-10.1177_10781552211067780 for Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort by Nadjoua Maouche, Anandagopal Srinivasan, Heather Leary, Freya Collings, Bing Tseu, Grant D Vallance, Karthik Ramasamy and Jaimal Kothari in Journal of Oncology Pharmacy Practice

Published
2021
Full Text
View/download PDF

8. Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre

Author

Gnanapragasam, Vincent J., primary, Thurtle, David, additional, Srinivasan, Anandagopal, additional, Volanis, Dimitrios, additional, George, Anne, additional, Lophatananon, Artitaya, additional, Stearn, Sara, additional, Warren, Anne Y., additional, Lamb, Alastair D., additional, Shaw, Greg, additional, Sharma, Naomi, additional, Thomas, Ben C., additional, Tran, Maxine G., additional, Neal, David E., additional, and Shah, Nimish C., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results